Studie JNJ-90189892 pro recidivující nebo refrakterní akutní myeloidní leukémii nebo myelodysplastické novotvary
Fáze 1, první u člověka, studie eskalace dávky JNJ-90189892 pro recidivující nebo refrakterní akutní myeloidní leukémii nebo myelodysplastické novotvary
The purpose of Part 1 (Dose Escalation) of the study is to assess the effective dose (recommended Phase 2 dose[s] [RP2Ds]) that can be safely administered, and dosing regimens of JNJ-90189892 in participants with relapsed or refractory (R/R) acute myeloid leukemia (AML) or R/R higher-risk type of myelodysplastic neoplasms (MDS [type of cancer of the blood and bone marrow, which does not respond to treatment or comes back after treatment]). The purpose of Part 2 (Cohort Expansion) is to further assess the safety, tolerability and efficacy in participants with R/R AML or higher-risk types of MDS at the RP2D regimen(s). The purpose of Part 3 and 4 is to assess the effective dose (recommended Phase 2 combination dose [RP2CD]) that can be safely administered, and dosing regimens of JNJ-90189892 in combination with azacitadine (AZA) + venetoclax (VEN) in participants with R/R AML (part 3) and newly diagnosed (ND) AML (part 4).
Přehled studie
Postavení
Postavení
Podmínky
Podmínky
Intervence / Léčba
Intervence / Léčba
Typ studie
Typ studie
Zápis (Aktuální)
Zápis
Fáze
Fáze
- Fáze 1
Kontakty a umístění
Studijní místa
-
-
-
Concord, Austrálie, 2139
- Concord Hospital
-
Melbourne, Austrálie, 3000
- Peter MacCallum Cancer Centre
-
Nedlands, Austrálie, 6009
- Sir Charles Gairdner Hospital
-
-
-
-
-
Marseille, Francie, 13273
- Institut Paoli-Calmettes
-
Strasbourg, Francie, 67200
- CHRU de Strasbourg - Hopital de Hautepierre
-
Toulouse, Francie, 31100
- Institut Claudius Regaud
-
-
-
-
-
Madrid, Španělsko, 28040
- Hosp Univ Fund Jimenez Diaz
-
Pamplona, Španělsko, 31008
- Clinica Univ. de Navarra
-
Seville, Španělsko, 41013
- Hospital Universitario Virgen Rocio
-
-
Kritéria účasti
Kritéria způsobilosti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- A. For Parts 1, 2, and 3: Have a diagnosis, per the world health organization (WHO) 2022 criteria, of (a) Parts 1, 2, and 3: Acute myeloid leukemia (AML) or (b) Parts 1 and 2: Moderate high, high, or very high-risk myelodysplastic neoplasms (MDS) per Molecular International Prognostic Scoring System (IPSS-M); B. For Part 4 only: Previously untreated acute myeloid leukemia (AML) per the WHO 2022 criteria
- Body weight that is greater than or equals to (>=) 40 kg
- Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
- Have adequate renal function defined as Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Estimated Glomerular Filtration Rate (eGFR) >=40 milligrams per minute (mL/min) computed with the calculator on the national kidney foundation website
- Participants must have laboratory parameters in the required range
Exclusion Criteria:
- Has a medical history of clinically significant pulmonary compromise, particularly the current need for supplemental oxygen use to maintain adequate oxygenation
- Has evidence of uncontrolled systemic viral, bacterial, or fungal infection. Antimicrobial prophylaxis is permitted
- All participants- Has known allergies, hypersensitivity, or intolerance to JNJ-90189892 or its excipients; Parts 3 and 4- Has known allergies, hypersensitivity, or intolerance to venetoclax (VEN), azacitadine (AZA), or their excipients
- Had major surgery or had significant traumatic injury within 14 days of planned first dose of JNJ-90189892
- Had a prior or concurrent second malignancy with natural history or treatment likely to interfere with any study endpoints of safety or the efficacy of the study treatment
- Has known active central nervous system involvement
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Nerandomizované
- Intervenční model: Sekvenční přiřazení
- Maskování: Žádné (otevřený štítek)
Počet zbraní
Zbraně a zásahy
Skupina účastníků / ArmSkupina účastníků / Arm |
Intervence / LéčbaIntervence / Léčba |
|---|---|
|
Experimentální: JNJ-90189892: Monotherapy
Participants will receive JNJ-90189892 in Part 1 (Dose escalation) of the study and the dose levels will be escalated sequentially based on the decisions of the study evaluation team (SET) until the recommended phase 2 dose (RP2D) has been identified. Participants in Part 2 (Dose expansion) will receive JNJ-90189892 at the RP2D determined in Part 1. |
JNJ-90189892 will be administered. |
|
Experimentální: JNJ-90189892: In Combination with Azacitadine (AZA)+ Venetoclax (VEN)
Participants with relapsed or refractory (R/R) acute myeloid leukemia (AML) in Part 3 will receive JNJ-90189892+ AZA+VEN to determine the recommended Phase 2 combination dose (RP2CD). The starting JNJ-90189892 dose regimen in Part 3 will be at least 1 dose level below the highest dose level cleared in Part 1 as determined by the SET. In Part 4 participants with newly diagnosed (ND) AML will receive JNJ-90189892+ AZA+VEN starting from the JNJ-90189892 dose level determined safe in Part 3 by the SET. |
JNJ-90189892 will be administered. AZA will be administered. VEN will be administered. |
Co je měření studie?
Primární výstupní opatření
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Number of Participants with Adverse events (AEs) by Severity
Časové okno: From screening untill 30 days after last dose of study drug (that is approximately 2.5 years)
|
An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event. |
From screening untill 30 days after last dose of study drug (that is approximately 2.5 years)
|
|
Part 1: Number of Participants with Dose-Limiting Toxicity (DLTs)
Časové okno: At least 14 days
|
DLT is defined as any toxicity that requires discontinuation of treatment, any Grade 5 toxicity; Non-hematologic toxicity (Grade 3 or 4) and Hematologic toxicity. |
At least 14 days
|
Sekundární výstupní opatření
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Serum Concentration of JNJ-90189892
Časové okno: Up to approximately 2.5 years
|
Serum samples will be analyzed to determine concentrations of JNJ-90189892. |
Up to approximately 2.5 years
|
|
Area Under the Curve Over a Dosing Interval (AUC tau) of JNJ-90189892
Časové okno: Up to approximately 2.5 years
|
AUC tau is the total observed plasma concentration of JNJ-90189892 in the body during the time between doses. AUCtau of JNJ-90189892 will be reported. |
Up to approximately 2.5 years
|
|
Maximum Observed Plasma Concentration (Cmax) of JNJ-90189892
Časové okno: Up to approximately 2.5 years
|
Cmax is the maximum observed plasma concentration of JNJ-90189892. Cmax of JNJ-90189892 will be reported. |
Up to approximately 2.5 years
|
|
Minimum Observed Plasma Concentration (Cmin) of JNJ-90189892
Časové okno: Up to approximately 2.5 years
|
Cmin is the minimum observed plasma concentration of JNJ-90189892. Cmin of JNJ-90189892 will be reported. |
Up to approximately 2.5 years
|
|
Number of Participants with Presence of Anti-JNJ-90189892 Antibodies
Časové okno: Up to approximately 2.5 years
|
Participants with presence of anti-JNJ-90189892 antibodies will be reported. |
Up to approximately 2.5 years
|
|
Complete Response (CR) in Acute Myeloid Leukemia (AML)
Časové okno: Up to approximately 2.5 years
|
CR is achieved when a participant has a best response of CR (including complete response with partial hematologic recovery [CRh] or complete response with incomplete hematologic recovery [CRi]) according to the European Leukemia Network (ENL) 2022 criteria. |
Up to approximately 2.5 years
|
|
Overall Response (OR) in Myelodysplastic Neoplasms (MDS)
Časové okno: Up to approximately 2.5 years
|
OR is achieved when a participant with MDS has a CR (any type, that is CRh or complete response with limited count recovery [CRL]), partial response (PR), or hematologic improvement (HI) according to the International Working Group (IWG) 2023 criteria. |
Up to approximately 2.5 years
|
|
Complete Response in MDS
Časové okno: Up to approximately 2.5 years
|
CR is achieved when a participant has a best response of CR (including CRh/CRL) according to the IWG 2023 criteria. |
Up to approximately 2.5 years
|
|
Duration of Response (DOR)
Časové okno: Up to approximately 2.5 years
|
DOR is defined for responsders only, as time from date of initial documentation of a response to the first documented evidence of no reponse, disease progression, relapse, initation of a new systemic anti-cancer therapy (besides hematopoietic stem cell transplant [HSCT]), or death, whichever comes first. |
Up to approximately 2.5 years
|
|
Time to Response (TTR)
Časové okno: Up to approximately 2.5 years
|
TTR is defined for responders, as the time from the first dose of study drug to first qualifying response. |
Up to approximately 2.5 years
|
|
Number of Participants Achieving Transfusion Independence
Časové okno: Up to approximately 2.5 years
|
Transfusion independence is defined as the absence of red blood cell (RBC) and platelet transfusions for 8 weeks or longer after starting study treatment for participants with AML and 16 weeks or longer for participants with MDS. |
Up to approximately 2.5 years
|
|
Part 4 Only: Overall Survival (OS)
Časové okno: Up to approximately 2.5 years
|
OS is defined as the time from the date of first dose of study treatment to the date of death due to any cause. |
Up to approximately 2.5 years
|
|
Part 4 Only: Event-Free Survival (EFS)
Časové okno: Up to approximately 2.5 years
|
EFS is defined as the time from the date of first dose of study treatment to the date of first documented evidence of treatment failure, relapse or death due to any cause, whichever occurs first. |
Up to approximately 2.5 years
|
Spolupracovníci a vyšetřovatelé
Sponzor
Sponzor
Vyšetřovatelé
Vyšetřovatelé
- Ředitel studie: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Začátek studia
Primární dokončení (Odhadovaný)
Primární dokončení
Dokončení studie (Odhadovaný)
Dokončení studie
Termíny zápisu do studia
První předloženo
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
První zveřejněno
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Poslední zveřejněná aktualizace
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
Další identifikační čísla studie
- 90189892AML1001
- 2024-514341-10-00 (Identifikátor registru: EUCT number)
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
produkt vyrobený a vyvážený z USA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .